Research analysts at Evercore ISI began coverage on shares of Qiagen (NASDAQ:QGEN) in a report released on Wednesday, January 3rd. The firm set an “outperform” rating and a $35.00 price target on the stock. Evercore ISI’s price target suggests a potential upside of 7.20% from the stock’s previous close.
QGEN has been the subject of a number of other research reports. TheStreet raised shares of Qiagen from a “c+” rating to a “b+” rating in a report on Tuesday, November 7th. Zacks Investment Research downgraded shares of Qiagen from a “buy” rating to a “hold” rating in a research note on Monday, October 16th. Cowen reaffirmed a “hold” rating and set a $34.00 price target on shares of Qiagen in a research note on Thursday, December 21st. Deutsche Bank reaffirmed a “buy” rating on shares of Qiagen in a research note on Wednesday, November 8th. Finally, Commerzbank reiterated a “buy” rating on shares of Qiagen in a research report on Tuesday, December 12th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company’s stock. Qiagen has an average rating of “Hold” and an average target price of $34.63.
Qiagen (NASDAQ QGEN) opened at $32.65 on Wednesday. Qiagen has a 52 week low of $27.51 and a 52 week high of $36.34. The company has a market cap of $7,540.00, a PE ratio of 83.72, a P/E/G ratio of 1.80 and a beta of 1.10. The company has a quick ratio of 4.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.68.
Qiagen (NASDAQ:QGEN) last announced its earnings results on Monday, November 6th. The company reported $0.32 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.32. Qiagen had a net margin of 6.40% and a return on equity of 11.36%. The firm had revenue of $364.00 million for the quarter, compared to analyst estimates of $363.42 million. During the same quarter in the prior year, the business posted $0.29 EPS. The business’s revenue was up 7.5% compared to the same quarter last year. equities analysts forecast that Qiagen will post 1.25 earnings per share for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its position in Qiagen by 4.6% in the second quarter. BlackRock Inc. now owns 8,203,013 shares of the company’s stock worth $275,048,000 after acquiring an additional 363,377 shares during the period. Vanguard Group Inc. raised its position in Qiagen by 7.0% in the second quarter. Vanguard Group Inc. now owns 6,053,863 shares of the company’s stock worth $202,986,000 after acquiring an additional 394,201 shares during the period. Frontier Capital Management Co. LLC increased its stake in shares of Qiagen by 0.7% in the third quarter. Frontier Capital Management Co. LLC now owns 2,554,021 shares of the company’s stock worth $80,452,000 after purchasing an additional 17,946 shares in the last quarter. State Street Corp increased its stake in shares of Qiagen by 2.1% in the second quarter. State Street Corp now owns 2,330,061 shares of the company’s stock worth $78,130,000 after purchasing an additional 48,679 shares in the last quarter. Finally, Legal & General Group Plc increased its stake in shares of Qiagen by 0.8% in the third quarter. Legal & General Group Plc now owns 1,909,956 shares of the company’s stock worth $52,573,000 after purchasing an additional 15,660 shares in the last quarter. 62.09% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Qiagen (NASDAQ:QGEN) Receives New Coverage from Analysts at Evercore ISI” was originally reported by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.truebluetribune.com/2018/01/13/qiagen-qgen-earns-outperform-rating-from-analysts-at-evercore-isi.html.
Qiagen Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.